Celanese and Secarna Pharmaceuticals Join Forces for RNA Research
Wednesday, 20 March 2024, 13:14
Celanese and Secarna Pharmaceuticals Collaborate for RNA Research
Celanese has joined hands with Secarna Pharmaceuticals to develop long-acting implants for delivering antisense oligonucleotides targeting various diseases. This partnership marks a significant step forward in the pharmaceutical industry, introducing innovative approaches to treatment delivery. The collaboration between these two entities signifies a focus on cutting-edge research and development, potentially leading to transformative therapies in the near future.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.